Clinical trials: Cervical Squamous Cell Carcinoma, Not Otherwise Specified
Renal Cell Carcinoma (RCC), Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
This is a multicenter Phase 1b, open label, dose-escalation and cohort-expansion study, evaluating the safety, tolerability, pharmacokinetics (PK), preliminary antitumor activity, and effect of biomarkers of zanzalintinib…
- Conditions
- Renal Cell Carcinoma (RCC), Metastatic Castration-Resistant Prostate Cancer (mCRPC), Urothelial Carcinoma (UC), Solid Tumor
- Trial name
- STELLAR-002 (NCT05176483)
- Testing
- Zanzalintinib, Nivolumab, Ipilimumab
- Where
- 122 sites in United States, Australia and 11 more
- Volunteers
- 1,394 people
- Sponsor
- Exelixis
Head and Neck Cancer
A Study to Assess the Effects of Multiple Study Drug Regimens in Subjects With Newly Diagnosed Locally Advanced Head and Neck Squamous Cell Carcinoma
A study evaluating the safety, pharmacokinetics, and biomarker profiles of multiple study drugs as monotherapy in subjects with newly diagnosed, treatment-naïve locally advanced squamous cell carcinoma of the head and neck who…
- Trial name
- NCT03818542
- Testing
- ABBV-181, ABBV-368, ABBV-927
- Where
- 3 sites in United States
- Volunteers
- 3 people
- Sponsor
- AbbVie
Esophageal Squamous Cell Carcinoma
Postoperative Concurrent Chemoradiotherapy Versus Radiotherapy Alone for Patients With Locoregionally Advanced Esophageal Squamous Cell Carcinoma
The aim of this study is to investigate the effect of postoperative concurrent chemoradiotherapy versus radiotherapy alone for patients with locally advanced esophageal squamous cell carcinoma.
- Trial name
- NCT03600831
- Testing
- Docetaxel plus cisplatin, radiotherapy
- Where
- 4 sites in China
- Volunteers
- 434 people
- Sponsor
- Huai'an First People's Hospital
Head and Neck Cancer
Curcumin Biomarker Trial in Head and Neck Cancer
There is considerable evidence that turmeric consumption may have a protective effect against cancer progression. The purpose of this study is to examine the short-term effects of supplementation with a turmeric extract, Curcumin…
- Trial name
- NCT01160302
- Testing
- Microgranular Curcumin C3 Complex®
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Louisiana State University Health Sciences Center Shreveport
Adult Giant Cell Glioblastoma, Adult Glioblastoma
18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy
The purpose of the study is to conduct research of a new PET radiopharmaceutical in cancer patients. The uptake of the novel radiopharmaceutical 18F-FPPRGD2 will be assessed in study participants with glioblastoma multiforme…
- Conditions
- Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Male Breast Cancer
- Trial name
- NCT01806675
- Testing
- 18F-fludeoxyglucose (18F-FDG), 18F-FPPRGD2
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Sanjiv Sam Gambhir
Esophageal Squamous Cell Carcinoma
PPIO-005 The Relationship Between Different Nutritional Pathways and Tumor Outcomes After Minimally Invasive Esophagectomy
As there is no consensus to date on the optimal postoperative nutritional support route for patients undergoing minimally invasive esophagectomy, the purpose of this study is to assess whether there is a potential advantage to…
- Trial name
- NCT06192212
- Where
- China
- Volunteers
- 577 people
- Sponsor
- Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Esophageal Squamous Cell Carcinoma
Endostar Combined With NVB and DDP Second-line Treatment of Advanced Esophageal Squamous Cell Carcinomas
The aim of this study is to explore whether endostar combined with NVB and DDP as treatment could improve progression-free surial time (PFS) and to evaluate the safety of the chemotherapy regimens
- Trial name
- NCT02665702
- Testing
- NVB, DDP, Endostar
- Where
- China
- Volunteers
- 76 people
- Sponsor
- Fudan University
Oropharynx Squamous Cell Carcinoma, Oropharynx Cancer
Circulating Biomarkers in Oropharyngeal Cancers
The goal of this observational longitudinal study is to learn about circulating tumor Human Papilloma Virus-DNA (ctHPV-DNA) as a biomarker for HPV positive oropharyngeal cancer and cancer of unknown primary of the head and neck.
- Conditions
- Oropharynx Squamous Cell Carcinoma, Oropharynx Cancer, Tonsillar Cancer, Base of the Tongue Carcinoma
- Trial name
- CIRCOS (NCT05904327)
- Where
- Sweden
- Volunteers
- 130 people
- Sponsor
- Region Örebro County
Stage I Adenoid Cystic Carcinoma of the Oral Cavity, Stage I Mucoepidermoid Carcinoma of the Oral Cavity
Esophagoscopy in Evaluating Treatment in Patients With Stage I-IV Head and Neck Cancer Who Are Undergoing Radiation Therapy and/or Chemotherapy
Brief Summary: RATIONALE: Comparing results of diagnostic procedures, such as esophagoscopy, done before and after radiation therapy and/or chemotherapy may help doctors predict a patient's response to treatment and help plan the…
- Conditions
- Stage I Adenoid Cystic Carcinoma of the Oral Cavity, Stage I Mucoepidermoid Carcinoma of the Oral Cavity, Stage I Squamous Cell Carcinoma of the Hypopharynx, Stage I Squamous Cell Carcinoma of the Larynx
- Trial name
- NCT01164566
- Testing
- endoscopic procedure, questionnaire administration
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Wake Forest University Health Sciences
Head and Neck Squamous Cell Carcinoma
A Clinical Study of SI-B001 in Combination With Paclitaxel/Docetaxel in the Treatment of Recurrent and Metastatic HNSCC
This Phase IIa study is a clinical trial to evaluate the safety and efficacy of SI-B001 in combination with paclitaxel or docetaxel in patients with recurrent or metastatic head and neck squamous cell carcinoma…
- Trial name
- NCT05054439
- Testing
- SI-B001, Paclitaxel, docetaxel
- Where
- 7 sites in China
- Volunteers
- 45 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Head and Neck Squamous Cell Carcinoma (HNSCC)
Study of Intratumoral (IT) Ulevostinag (MK-1454) in Combination With Intravenous (IV) Pembrolizumab (MK-3475) Compared to IV Pembrolizumab Alone as the First Line Treatment of Metastatic or Unresectable, Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC) (MK-1454-002)
The purpose of this study is to assess the efficacy and safety of intratumoral (IT) ulevostinag PLUS pembrolizumab (MK-3475) compared to pembrolizumab alone as a first line treatment of adults with metastatic or unresectable…
- Trial name
- NCT04220866
- Testing
- Ulevostinag, Pembrolizumab
- Where
- 34 sites in United States, Australia and 8 more
- Volunteers
- 18 people
- Sponsor
- Merck Sharp & Dohme LLC
Oropharynx Cancer, Larynx Cancer
Lymphocyte-Sparing And Radio-Immunotherapy in Head and Neck Carcinoma
The aim of this study is to investigate the effect of ATRA (Vesanoid) and the effect of tailored radiotherapy in patients with squamous cell carcinoma of the oropharynx, larynx or hypopharynx.
- Conditions
- Oropharynx Cancer, Larynx Cancer, Hypopharynx Cancer, Primary Head and Neck Tumor
- Trial name
- LYSARI (NCT06706401)
- Testing
- Vesanoid, Standard radiotherapy, Tailored radiotherapy
- Where
- 8 sites in France
- Volunteers
- 460 people
- Sponsor
- Centre Leon Berard
Head and Neck Cancer, Precancerous Condition
Induction Chemotherapy Followed By Cetuximab and Radiation in HPV-Associated Resectable Stage III/IV Oropharynx Cancer
RATIONALE: Drugs used in chemotherapy, such as paclitaxel and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT01084083
- Testing
- cetuximab, intensity-modulated radiation therapy (IMRT), Paclitaxel
- Where
- 121 sites in United States
- Volunteers
- 90 people
- Sponsor
- Eastern Cooperative Oncology Group
Squamous Cell Carcinoma of Head and Neck
Safety and Efficacy Study of P276-00 in Combination With Radiation in Subjects With Advanced Head and Neck Cancer
The purpose of this study is to identify a dose of P276-00 that can be safely administered along with Radiation and to examine safety and efficacy of the combination in treatment of advanced head and neck cancer.
- Trial name
- SPARK (NCT00899054)
- Testing
- P276-00, External beam radiotherapy (EBRT)
- Where
- 6 sites in India
- Volunteers
- 23 people
- Sponsor
- Piramal Enterprises Limited
Head and Neck Squamous Cell Carcinoma
Platinum-Cetuximab Combined With Docetaxel or With 5FU in Patients With Recurrent/Metastatic HNSCC
This study evaluates the efficacy of the new docetaxel-cisplatin-cetuximab regimen (TPEx) versus the standard platinum-5FU-cetuximab EXTREME regimen as a first-line treatment in recurrent and/or metastatic HNSCC.
- Trial name
- TPExtreme (NCT02268695)
- Testing
- Cisplatin, 5-Fluorouracile, Docetaxel
- Where
- 17 sites in France, Germany and 1 more
- Volunteers
- 541 people
- Sponsor
- Groupe Oncologie Radiotherapie Tete et Cou
Esophageal Squamous Cell Carcinoma, Gastric Carcinoma, Gastroesophageal Junction Carcinoma
BGB A317 in Combination With Chemotherapy as First-Line Treatment in Adults With Inoperable, Locally Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction Carcinoma
This is a Phase 2, multi-cohort study to investigate safety, PK, and preliminary anti-tumor activity of the monoclonal antibody BGB A317 in combination with standard chemotherapy as first-line treatment.
- Trial name
- NCT03469557
- Testing
- Tislelizumab, Cisplatin, 5-FU
- Where
- 6 sites in China
- Volunteers
- 30 people
- Sponsor
- BeiGene
Head and Neck Cancer
Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Head and Neck Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00006051
- Testing
- cisplatin, fluorouracil, radiation therapy
- Where
- 6 sites in France
- Sponsor
- UNICANCER
Recurrence, Metastasis
Prognostic Value of CTC in HNSCC Patients
We hypothesized that the number of circulating tumor cells (CTCs) and molecular markers on CTCs could be a prognostic factor or predictive factor to patients with head neck cancer.
- Conditions
- Recurrence, Metastasis, Death
- Trial name
- CTCHNSCC01 (NCT01884129)
- Where
- Taiwan
- Volunteers
- 53 people, healthy volunteers welcome
- Sponsor
- Chang Gung Memorial Hospital
HPV-Related Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma
HPV-16 Vaccination and Pembrolizumab Plus Cisplatin for "Intermediate Risk" HPV-16-associated Head and Neck Squamous Cell Carcinoma
This clinical trial will evaluate a new combination of pembrolizumab, HPV-16 E6/E7 specific therapeutic vaccination (ISA101b) and cisplatin-based chemoradiotherapy for patients with newly diagnosed, local-regionally advanced…
- Trial name
- NCT04369937
- Testing
- IMRT (Intensity Modulated Radiotherapy), Pembrolizumab, Cisplatin
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Dan Zandberg
Neoplasms
Phase I Dose Escalation Study for VIP152 in Patients With Advanced Cancer
Determine the safety, tolerability, pharmacokinetics, maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) of VIP152 (BAY 1251152) as monotherapy or in combination in patients with solid tumors and aggressive…
- Trial name
- NCT02635672
- Testing
- VIP152 (BAY 1251152), VIP152 (BAY 1251152) 30 mg, Keytruda
- Where
- 16 sites in United States, Chile and 1 more
- Volunteers
- 110 people
- Sponsor
- Vincerx Pharma, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.